MICHAEL MICHELAKIS: Open Payments
NPI 1235176249 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$510 in 13 payments from 9 companies in 2025. Trend: 2023 $597 · 2024 $738 · 2025 $510
Food & beverage: $438Education: $73
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $170 |
| Neurocrine BioSciences, Inc. | 1 | $73 |
| Teva Pharmaceuticals USA, Inc. | 1 | $73 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| ABBVIE INC. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Lundbeck LLC | 1 | $31 |
| Alkermes, Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: REXULTI, INGREZZA, FANAPT, VRAYLAR, Auvelity, ARISTADA, COBENFY.
Industry payments across MI — which companies pay providers there.
